Capital Com SV Investments Limited
Integration of Newsquawk's AI-powered news feeds will be made available to retail traders for the first time
LONDON, UNITED KINGDOM / ACCESSWIRE / August 8, 2024 / Capital.com, the global trading platform whose trading client volumes surpassed $1trn in 2023, today announced a strategic partnership with leading market real-time news platform, Newsquawk. With this partnership, Capital.com clients will have access to instant, market-moving news typically reserved for institutional and professional traders.
Through an API integration, Newsquawk feeds will be delivered directly via the Capital.com app and web platforms, enabling more than 500,000 retail clients to receive up-to-the-minute news feeds. This partnership marks an industry-first in the retail brokerage space, affirming Capital.com's commitment to help clients make informed trading decisions.
Dana Massey, Chief Product Officer, Capital.com, said:
"This partnership with Newsquawk reflects our ongoing commitment to support our traders with market-moving news and analysis to help inform their next move. This is the first time Newsquawk's institutional-grade service is being offered to retail traders and we are proud to be their partner in this journey. This is a massive step towards levelling the playing field, empowering traders to act with confidence and without delay."
Mehul Patel, Founder, Newsquawk, said:
"We are thrilled to work with Capital.com and extend our real-time news services to a broader audience. Powered by our proprietary news filtering technology and analysts, Newsquawk aggregates thousands of headlines and data releases across newswires, social media and live tv broadcasts to find the news that will move the market. Testament to the strength of our groundbreaking technology, Newsquawk has recently been awarded the prestigious 2024 UK Innovate Grant. We are excited to support Capital.com's retail clients and enhance their trading experience with rapid, reliable, and actionable news."
Niamh Byrne, Head of UK & Ireland, Capital.com, said:
"We have a long-standing partnership with Newsquawk in the UK, and our clients have always valued the service they provide. Recognising its importance, we decided to integrate Newsquawk into our web & mobile apps, ensuring all our clients can access the same reliable breaking news and alerts that institutional and professional traders depend on daily."
Key features of the partnership include:
Immediate Access to Market-Moving News: Capital.com traders will receive up-to-the-minute information that can impact market movements, incorporating both scheduled announcements and unscheduled news that could affect the markets.
Global Coverage: Traders will receive sector specific market coverage, including equities, currencies, commodities, and bonds, appealing to traders with diverse interests.
Expert Analysis: Access to expert commentary, produced by a team of qualified analysts, to help traders understand the implications of news events to support more informed trading decisions.
Headlines and Reports: Breaking news headlines and reports delivered directly to clients' mobile devices in multiple languages, helping them to trade the news without delay.
The integration will be rolled out in phases. The first phase, which includes access to Newsquawk's breaking news feeds, is currently available to all Capital.com clients actively trading on the platform. Further features of the product integration will be progressively rolled out over the coming months.
ENDS/
Media Contact
PR for Capital.com
Shamillia.sivathambu@capital.com
+44 7900 016 469
Notes to Editors
About Newsquawk
Newsquawk is a breaking financial news provider for institutional and professional traders. The company was recently awarded the prestigious 2024 Innovate UK Grant to develop its groundbreaking Large Language Model (LLM) project leveraging its proprietary data sets and market knowledge. LLMs, a subset of Artificial Intelligence(AI), are very large deep learning models that are pre-trained on vast amounts of data. Newsquawk's LLM(s) will leverage a decade of proprietary news data to provide traders with unparalleled and instantaneous context around market impacting events.
About Capital.com
Capital.com is a high-growth fintech company empowering people to participate in financial markets through simple and innovative online trading platforms. Launched in 2016, its intuitive award-winning platform -available on web and app -enables investors to trade thousands of world-renowned markets. To help investors trade with confidence, the platform is fitted with robust risk management controls, transparent pricing and extensive educational content to support clients in their trading journeys.
Capital.com has a global network with offices located in leading business and financial centres including London, Dubai, Warsaw, Vilnius, Sofia, Limassol, and Melbourne. Capital Com (UK) Limited is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 793714. Capital Com SV Investments Limited is Authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC), under licence number 319/17. Capital Com Australia Pty Ltd is authorised and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL Number 513393. Capital Com Online Investments Ltd is a Company registered in the Commonwealth of The Bahamas and authorised to carry out Securities Business by the Securities Commission of The Bahamas with licence number SIA-F245. Capital Com Mena Securities Trading LLC is authorised and regulated by the Securities and Commodities Authority (SCA), under license number 20200000176.
To find out more, please visit: www.capital.com
This press release is for media use only. It's not intended for individual investors, and doesn't include personal advice or recommendations.
DISCLAIMER
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 83.51% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money. Professional clients can lose more than they deposit. All trading involves risk.
Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd. Spread bets are available only to UK clients.
The value of shares and ETFs bought through a share dealing account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
Capital Com (UK) Limited ("CCUK") is registered in England and Wales with company registration number 10506220. CCUK is authorised and regulated by the Financial Conduct Authority ("FCA"), under registration number 793714. Capital Com SV Investments Limited ("CCSV") is registered in Cyprus with company registration number 354252. CCSV is regulated by Cyprus Securities and Exchange Commission (CySEC) under licence number 319/17. Capital Com Online Investments Ltd is a limited liability company (company number 209236B) registered in the Commonwealth of The Bahamas and authorised to carry on Securities Business by the Securities by the Securities Commission of The Bahamas ("SCB") with licence number SIA-F245. Capital Com Mena Securities Trading LLC is authorised and regulated by the Securities and Commodities Authority (SCA), under license number 20200000176.
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
Any information which could be construed as "investment research" has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.
SOURCE: Capital Com SV Investments Limited
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release
SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu
Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release
Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom